HIG:NYSEThe Hartford Insurance Group, Inc. Analysis
Data as of 2026-03-10 - not real-time
$137.95
Latest Price
3/10Risk
Risk Level: Low
Executive Summary
The Hartford (HIG) trades around $138, well below its DCF‑derived fair value of roughly $384, indicating a **substantial undervaluation** of over 170%. Its trailing P/E of 10.3 is markedly lower than the industry average of 17.4, and the forward P/E of 9.5 reinforces the value case. Operating margins remain solid at 20% with an ROE of 21.6%, while a modest payout ratio of 16% and a 1.74% dividend yield suggest the dividend is **highly sustainable** given robust free cash flow of $5.8 bn. Technicals show a bullish trend direction, price sitting above the 50‑day SMA and near the identified support at $136, though the MACD is currently bearish, implying short‑term caution. Analyst consensus is a “Buy” with a median price target of $150, offering an upside of about 9% from current levels, and the market sentiment index is in “Extreme Greed” territory, supporting a contrarian entry.
Overall, the combination of deep valuation discount, strong profitability, low beta (0.52) and stable volume makes HIG an attractive **blend** of growth and value, suitable for investors seeking a defensive play with upside potential. The modest volatility (≈18% 30‑day) and low liquidity risk further enhance its appeal across short, medium, and long horizons.
Overall, the combination of deep valuation discount, strong profitability, low beta (0.52) and stable volume makes HIG an attractive **blend** of growth and value, suitable for investors seeking a defensive play with upside potential. The modest volatility (≈18% 30‑day) and low liquidity risk further enhance its appeal across short, medium, and long horizons.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Price near technical support at $136
- Significant valuation gap to DCF fair value
- Stable dividend with low payout ratio
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Analyst consensus buy and median target $150
- Strong operating cash flow and ROE
- Low beta indicating defensive characteristics
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Sustained premium growth and underwriting margin stability
- Long‑term upside potential from undervaluation
- Resilient dividend policy and solid balance sheet
Key Metrics & Analysis
Financial Health
Revenue Growth6.70%
Profit Margin13.52%
P/E Ratio10.3
ROE21.66%
ROA3.72%
Debt/Equity23.94
P/B Ratio2.0
Op. Cash Flow$5.9B
Free Cash Flow$5.8B
Industry P/E17.4
Technical Analysis
TrendBullish
RSI44.8
Support$136.06
Resistance$143.98
MA 20$140.97
MA 50$137.44
MA 200$131.34
MACDBearish
VolumeStable
Fear & Greed Index76.93
Valuation
Fair Value$383.92
Target Price$150.85
Upside/Downside9.35%
GradeUndervalued
TypeBlend
Dividend Yield1.74%
Risk Assessment
Beta0.52
Volatility17.83%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.